These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 31464745)

  • 1. Reporting Adverse Drug Events.
    Feagins LA; Abdelsayed GG; Schairer J;
    Am J Gastroenterol; 2019 Sep; 114(9):1411-1413. PubMed ID: 31464745
    [No Abstract]   [Full Text] [Related]  

  • 2. Postmarket Safety Outcomes for New Molecular Entity (NME) Drugs Approved by the Food and Drug Administration Between 2002 and 2014.
    Pinnow E; Amr S; Bentzen SM; Brajovic S; Hungerford L; St George DM; Dal Pan G
    Clin Pharmacol Ther; 2018 Aug; 104(2):390-400. PubMed ID: 29266187
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The missing voice of patients in drug-safety reporting.
    Basch E
    N Engl J Med; 2010 Mar; 362(10):865-9. PubMed ID: 20220181
    [No Abstract]   [Full Text] [Related]  

  • 4. Safety of newly approved drugs: implications for prescribing.
    Temple RJ; Himmel MH
    JAMA; 2002 May; 287(17):2273-5. PubMed ID: 11980528
    [No Abstract]   [Full Text] [Related]  

  • 5. New FDA initiatives.
    Somberg JC
    J Clin Pharmacol; 1993 Jul; 33(7):587. PubMed ID: 8366185
    [No Abstract]   [Full Text] [Related]  

  • 6. Bringing the FDA's Information to Market.
    Woloshin S; Schwartz LM
    Arch Intern Med; 2009 Nov; 169(21):1985-7. PubMed ID: 19933960
    [No Abstract]   [Full Text] [Related]  

  • 7. Assessing drug safety and consequences of drug withdrawals.
    Mamdani M
    J Am Pharm Assoc (2003); 2004; 44(6):659-60. PubMed ID: 15637847
    [No Abstract]   [Full Text] [Related]  

  • 8. Analysis of factors related to the occurrence of important drug-specific postmarketing safety-related regulatory actions: A cohort study focused on first-in-class drugs.
    Ikeda J; Kaneko M; Narukawa M
    Pharmacoepidemiol Drug Saf; 2018 Dec; 27(12):1393-1401. PubMed ID: 30094880
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions.
    Wysowski DK; Swartz L
    Arch Intern Med; 2005 Jun; 165(12):1363-9. PubMed ID: 15983284
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How to evaluate the benefit-risk profile of newly marketed drugs.
    Naldi L
    Ann Dermatol Venereol; 2010 Apr; 137(4):264-6, 261-3. PubMed ID: 20417357
    [No Abstract]   [Full Text] [Related]  

  • 11. IOM: overhaul drug safety monitoring.
    Kuehn BM
    JAMA; 2006 Nov; 296(17):2075-6. PubMed ID: 17077364
    [No Abstract]   [Full Text] [Related]  

  • 12. Drug withdrawals in the United States: a systematic review of the evidence and analysis of trends.
    Issa AM; Phillips KA; Van Bebber S; Nidamarthy HG; Lasser KE; Haas JS; Alldredge BK; Wachter RM; Bates DW
    Curr Drug Saf; 2007 Sep; 2(3):177-85. PubMed ID: 18690965
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Era of faster FDA drug approval has also seen increased black-box warnings and market withdrawals.
    Frank C; Himmelstein DU; Woolhandler S; Bor DH; Wolfe SM; Heymann O; Zallman L; Lasser KE
    Health Aff (Millwood); 2014 Aug; 33(8):1453-9. PubMed ID: 25092848
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The importance of physicians identifying and reporting adverse drug events.
    Gatti JC
    Am Fam Physician; 2012 Feb; 85(4):318. PubMed ID: 22335311
    [No Abstract]   [Full Text] [Related]  

  • 15. [Direct reporting by patients of adverse drug reactions in Spain].
    Esther Salgueiro M; Jimeno FJ; Aguirre C; García M; Ordóñez L; Manso G
    Farm Hosp; 2013; 37(1):65-71. PubMed ID: 23461502
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 'Extreme duplication' in the US FDA Adverse Events Reporting System database.
    Hauben M; Reich L; DeMicco J; Kim K
    Drug Saf; 2007; 30(6):551-4. PubMed ID: 17536881
    [No Abstract]   [Full Text] [Related]  

  • 17. Drug Manufacturers' Delayed Disclosure of Serious and Unexpected Adverse Events to the US Food and Drug Administration.
    Ma P; Marinovic I; Karaca-Mandic P
    JAMA Intern Med; 2015 Sep; 175(9):1565-6. PubMed ID: 26214395
    [No Abstract]   [Full Text] [Related]  

  • 18. FDA Encourages Reporting of Tobacco Product Adverse Experiences.
    Retzky SS
    Chest; 2016 Dec; 150(6):1169-1170. PubMed ID: 27938736
    [No Abstract]   [Full Text] [Related]  

  • 19. Assessment of the impact of scheduled postmarketing safety summary analyses on regulatory actions.
    Sekine S; Pinnow EE; Wu E; Kurtzig R; Hall M; Dal Pan GJ
    Clin Pharmacol Ther; 2016 Jul; 100(1):102-8. PubMed ID: 26853718
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety concerns at the FDA.
    Lancet; 2005 Feb 26-Mar 4; 365(9461):727-8. PubMed ID: 15733696
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.